GLP-1 Drugs Linked to Reduced Substance Use Disorders in US Veterans | Research

The takeaway

Large veteran cohort study finds GLP-1 receptor agonists associated with reduced risk of new substance use disorders and better outcomes in those with existing addictions.

6 substance categories, 2 protocols
GLP-1 RAs associated with reduced addiction risk and improved SUD outcomes in veterans

What the researchers found

GLP-1 RA initiation was associated with reduced incidence of alcohol, cannabis, cocaine, nicotine, opioid, and other SUDs in veterans without prior addictions, and reduced adverse outcomes in those with pre-existing SUDs.

Why it matters

Substance use disorders affect millions and have limited treatments. If GLP-1 drugs reduce addiction risk, they could benefit an enormous population beyond diabetes patients.

How the study worked

Target trial emulation using veteran cohort data with two protocols: (1) incident SUD risk in SUD-free veterans, (2) clinical outcomes in veterans with pre-existing SUDs, comparing GLP-1 RA initiators to non-users.

What this study cannot tell us

Observational study — cannot prove causation. Veterans may not represent the general population. Healthy user bias possible.

How to read the evidence

Large observational cohort with target trial emulation — strong methodology for observational evidence, but causation not established.

When this study was published

Published in 2026; among the most comprehensive studies of GLP-1 drugs and addiction.

The bigger picture

This adds to growing evidence that GLP-1 receptor signaling modulates reward pathways, positioning these drugs as potential treatments for addiction — a paradigm-shifting possibility.

Questions still open

Should GLP-1 drugs be tested in dedicated addiction treatment trials?
Does the anti-addiction effect persist after GLP-1 drug discontinuation?

Common questions

Can GLP-1 drugs help with addiction?

This large study of US veterans found that people who started GLP-1 drugs had lower rates of developing substance use disorders and better outcomes if they already had addictions. Clinical trials are needed to confirm this potential benefit.

How might weight loss drugs reduce addiction?

GLP-1 receptors are found in brain reward centers that drive both food cravings and substance addiction. By modulating these pathways, GLP-1 drugs may reduce the neurological drive behind addictive behaviors.

Read the original research

Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.

BMJ (Clinical research ed.), 392, e086886

View on PubMed ↗Publisher’s paper ↗

Citation

Cai, Miao; Choi, Taeyoung; Xie, Yan; Al-Aly, Ziyad. (2026). Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study.. BMJ (Clinical research ed.), 392, e086886. https://doi.org/10.1136/bmj-2025-086886